冠状动脉PCI合并心房颤动患者的抗栓治疗

Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI

心房颤动(房颤)增加血栓栓塞并发症的风险,包括脑卒中和颅外的全身性栓塞事件,这呼吁行口服抗凝剂(oral anticoagulation,OAC)预防性治疗。估计20%~40%的房颤患者患有冠心病,其中相当比例的患者需要行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)和植入支架再血管化治疗。这类患者需要血小板双抗治疗(dual antiplatelet therapy,DAPT)来防范支架血栓形成和其他血栓性缺血事件。

Atrisl fibrillation(AF)increases the risk of thromboembolic complications,including stroke and extracranial systemic embolic events,which call for therapeutic prophylaxis with oral anticoagulation(OAC).It is estimated that about 20%to 40%of patients with AF also present with coronary artery disease(CAD),a sizeable proportion of whom requires revascularization using percutaneous coronary intervention(PCI)and stent implantation.Such patients need dual antiplatelet therapy(dual antiplatelet therapy,DAPT)to prevent the risk of stent thrombosis and additional thrombotic ischemic events.